❌

Normal view

Received — 1 June 2026 ⏭

Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo

✇Ars Technica - All
By: Beth Mole
1 June 2026 at 21:58

The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday that it will "urgently accelerate development" of three vaccine candidates against Bundibugyo ebolavirus (BDBV), pledging a little over $60 million in the effort to extinguish an outbreak currently raging out of control in the Democratic Republic of the Congo.

Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate. The funding will simultaneously allow the company to ramp up manufacturing capabilities and ready large-scale Phase 2/3 trials in the event the vaccine makes it through early testing. The vaccine will use Moderna's mRNA vaccine platform that allowed for rapid development of a COVID-19 vaccine during the pandemic.

"[W]e believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," Moderna CEO Stéphane Bancel said in a statement Monday. " We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."

Read full article

Comments

© Getty | GLODY MURHABAZI

Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo

✇Ars Technica
By: Beth Mole
1 June 2026 at 21:58

The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday that it will "urgently accelerate development" of three vaccine candidates against Bundibugyo ebolavirus (BDBV), pledging a little over $60 million in the effort to extinguish an outbreak currently raging out of control in the Democratic Republic of the Congo.

Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate. The funding will simultaneously allow the company to ramp up manufacturing capabilities and ready large-scale Phase 2/3 trials in the event the vaccine makes it through early testing. The vaccine will use Moderna's mRNA vaccine platform that allowed for rapid development of a COVID-19 vaccine during the pandemic.

"[W]e believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," Moderna CEO Stéphane Bancel said in a statement Monday. " We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."

Read full article

Comments

© Getty | GLODY MURHABAZI

This could be Windows’ M1 moment — but expect it to cost a ton

✇The Verge - All Posts
By: Antonio G. Di Benedetto
1 June 2026 at 21:02
Nvidia CEO Jensen Huang holds up two RTX Spark laptops at Computex 2026

Nvidia's announcement that it's getting into the consumer laptop chip space with RTX Spark is huge. Apple has proved for years that Arm-based chips can perform incredibly well while also delivering great battery life - at least on the Mac. In the Windows world, performance hasn't fully matched up under Qualcomm chips, mostly in the graphics department. There's clearly still untapped potential, and Nvidia seems to be promising to deliver it.

This could be Windows' moment to blow us away with a new generation of supremely capable chips, much like Apple's back in 2020, with the introduction of the M1. But why does this launch feel simultaneous …

Read the full story at The Verge.

❌